PROTAC JAK2 degrader-1
PROTAC JAK2 degrader-1 is a JAK2 PROTAC degrader, with a DC50 of 27.35 nM. PROTAC JAK2 degrader-1 induces JAK2 degradation via the ubiquitin-proteasome pathway. PROTAC JAK2 degrader-1 inhibits the JAK2-STAT signaling pathway. PROTAC JAK2 degrader-1 induces G2/M phase arrest and apoptosis in cancer cells. PROTAC JAK2 degrader-1 exhibits antiproliferative activity against cancer cells. PROTAC JAK2 degrader-1 inhibits recombinant human erythropoietin (rhEPO)-mediated polycythemia and splenomegaly in mice. PROTAC JAK2 degrader-1 can be used for research on myeloproliferative neoplasms, including polycythemia vera.
(Pink: JAK2 ligand (HY-174430); Blue: Cereblon ligand (HY-W087383); Black: linker).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C45H51ClFN9O5
- Peso molecular:852.40
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas PROTACs
More
Actividad biológica
Descripciòn
IC50 & Target
|
p-STAT3 |
STAT5 |
JAK2-V617F 27.35 nM (DC50) |
Cereblon |
In Vitro
PROTAC JAK2 degrader-1 (Compound 10i) (8 nM-5 μM; 24 h) potently degrades JAK2V617F protein in SET-2 cells via a proteasome-dependent pathway, with a DC50 of 27.35 nM and a degradation rate of up to 91.32% after 24 h of treatment at 5 μM[1].
PROTAC JAK2 degrader-1 (8 nM-5 μM; 24 h) inhibits the JAK2-STAT signaling pathway in SET-2 cells in a dose-dependent manner by reducing the phosphorylation levels of JAK2, STAT3 and STAT5[1].
PROTAC JAK2 degrader-1 potently inhibits the proliferation of SET-2 cells with an IC50 of 0.12 μM; it also inhibits the proliferation of HEL cells with an IC50 of 1.43 μM[1].
PROTAC JAK2 degrader-1 (0-1 μM, 24 h) blocks the G2/M cell cycle progression of SET-2 cells and induces apoptosis in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SET-2 cells (carrying JAK2 V617F mutation)
-
Concentration:8 nM, 40 nM, 200 nM, 1 μM, 5 μM
-
Incubation Time:24 h
-
Result:Induced dose-dependent degradation of JAK2 V617F protein in SET-2 cells, achieving degradation rates of 15.12% at 8 nM, 56.91% at 40 nM, 76.45% at 200 nM, 78.40% at 1 μM, and 91.32% at 5 μM.
Achieved a DC50 of 27.35 nM.\nDose-dependently inhibited phosphorylation of JAK2, STAT3, and STAT5 in SET-2 cells, with no significant effect on total STAT3 and STAT5 protein levels.
-
Cell Line:Jurkat cells
-
Concentration:8 nM, 40 nM, 200 nM, 1 μM, 5 μM
-
Incubation Time:24 h
-
Result:Showed no significant degradation of JAK1, JAK3, TYK2, or GSPT1 in Jurkat cells even at the highest tested concentration of 5 μM.
-
Cell Line:SET-2 cells
-
Concentration:0, 0.1, 1 μM
-
Incubation Time:24 h
-
Result:Blocked the G2/M cell cycle progression.
-
Cell Line:SET-2 cells
-
Concentration:0, 0.1, 1 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis in a dose-dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 8−10 weeks, 20−25 g, rhEPO-induced polycythemia and splenomegaly)[1]
-
Dosage:30 mg/kg
-
Administration:i.p.; daily; 4 days
-
Result:Reduced reticulocyte count from 18.25% (model group) to 10.94%.
Reduced hematocrit from 49.80% (model group) to 44.81%.
Decreased the proportion of Ter119/CD71 positive erythroid progenitor cells in the spleen from 41.25% (model group) to 25.43% and in bone marrow from 19.71% (model group) to 6.16%.
Reduced average spleen weight from 0.269 g (model group) to 0.216 g.
Decreased JAK2 protein levels and suppressed phosphorylation of STAT3 and STAT5 in spleen tissue.
Chemical Information
-
Peso molecular 852.40
-
Fòrmula C45H51ClFN9O5
-
SMILES
FC1=CC([C@H](OC2=C(N=CC(C3=CN(N=C3)C4CCN(CC4)CC5CN(CC5)CC6CCN(CC6)C7=CC(C(N8C9CCC(NC9=O)=O)=O)=C(C=C7)C8=O)=C2)N)C)=C(C=C1)Cl
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)